DoseGear research brief
Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.
DG Peptide Protocols
Well StudiedWeight LossGrowth Hormone
CJC-1295 with DAC
CJC-1295 DAC
Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release
Research overview
Mechanism of action
DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.
Compound background
Development & research timeline
Study windows describe what researchers measured, not when an individual should expect a result.
Origin & development
Albumin-binding, long-acting GHRH analog associated with ConjuChem development.
What it is researched for
Sustained growth-hormone and IGF-I stimulation through GHRH-receptor agonism and covalent albumin attachment.
Research observation window
A human study measured increased GH for at least six days and IGF-I for 9–11 days after one injection; these were hormone measurements, not physique outcomes.
Reference data
Lyophilized vial injectable protocols
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Conservative Anti-Aging | 1mg | Once weekly | SubQ |
| Standard Protocol | 2mg | Once weekly | SubQ |
| Split Dosing | 1mg | Twice weekly (Mon/Thu) | SubQ |
| Loading Protocol | 2mg first week, then 1mg | Weekly | SubQ |
Reference cycle
8-12 weeks
Reference storage
Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 30 days
Safety context
Reported side effects
- Water retention
- Joint pain
- Carpal tunnel symptoms
Contraindications & cautions
- Diabetes history
- Cancer history
- Predisposed sleep apnea
Scientific references
- 01
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
Scientific citationProlonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism (2006). - 02
Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog
Scientific citationPulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. Journal of Clinical Endocrinology & Metabolism (2006). - 03
Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog
Scientific citationHuman Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology (2005). - 04
Activation of the GH/IGF-1 Axis by CJC-1295, a Long-Acting GHRH Analog, Results in Serum Protein Profile Changes in Normal Adult Subjects
Scientific citationActivation of the GH/IGF-1 Axis by CJC-1295, a Long-Acting GHRH Analog, Results in Serum Protein Profile Changes in Normal Adult Subjects. Growth Hormone & IGF Research (2009).
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.